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ABSTRACT

THE ROLE OF SPHINGOLIPIDS IN AKI AND THE PROGRESSION TO CKD:
POTENTIAL THERAPUETIC TARGETS
Nicholas A. Hoffman
November 11, 2021
Acute Kidney Injury (AKI) is most simply defined as a rapid decline in
kidney function over a period of hours to days. There is currently a lack of
effective treatment options for patients with AKI, highlighting the need to identify
new therapeutic targets. Sphingolipids play a number of roles in different models
of AKI, suggesting they could be promising future targets for treating kidney
injury. Specifically, sphingosine-1-phosphate (S1P) and its receptors (S1PRs)
have been implicated in numerous inflammatory disorders and models of AKI.
The purpose of this review is to better characterize the role of S1P receptors in
models of AKI and to highlight key limitations in drug development.
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DISCUSSION
KIDNEY FUNCTION
The kidneys are responsible for many fundamental physiological
functions: pH balance, and electrolyte composition, filtration and elimination of
metabolic and toxic wastes from the blood, regulation of the internal fluid
environment to maintain proper fluid volume and tonicity, essential endocrine
functions such as erythropoiesis and blood pressure regulation, and the
metabolism and excretion of many drugs [1]. The kidneys are located along the
posterior abdomen wall, divided into two sections: the outer cortex and the inner
medulla [2]. Within these two sections are associated vasculature, nerves,
lymphatic vessels and nephrons. Nephrons are the functional units of the kidney,
consisting of the glomerulus, Bowman capsule, and renal tubule [2]. On average,
each kidney is comprised of 1 million nephrons, accounting for nearly 25% of
cardiac output [2]. Fluids flows through each successive section of the nephron,
undergoing a sophisticated process of excretion and reabsorption to maintain
fluid homeostasis [2].
The glomerulus is a complex capillary network responsible for
ultrafiltration of blood plasma and solute clearance; the glomerular capillaries are
positioned between the efferent and afferent arterioles [2]. This configuration
allows for tight regulation of glomerular pressure and glomerular filtration rate
(GFR). GFR is the product of capillary surface area and filtration pressure, with
1

the average adult GFR around 130 mL/min[2]. Despite the significance of the
kidney, there is a huge gap in treatment for patients who suffer from decreased
kidney function. A loss in kidney function, over a period of hours up to several
days, commonly referred to as acute kidney injury (AKI), can result in a myriad of
clinical manifestations and sequelae [3]. Due to the significance of the kidney,
there is a push for more sensitive biomarkers and treatments for AKI.
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ACUTE KIDNEY INJURY
Acute kidney injury (AKI) and its severity are defined differently amongst
clinics; changes in both urine output and serum creatinine are generally used to
diagnose the severity of injury. At its most basic definition, AKI is defined as a
significant decrease in glomerular filtration rate (GFR) and an increase in
retained waste products over a few days [3]. It has been known that a large
portion of hospital inpatients experience AKI, making it one of the most common
conditions linked with hospital stays. Since 2002, nearly 25% of patients admitted
into the hospital develop AKI; AKI development significantly increases the
patients risk of mortality compared to patients without AKI [4]. In 2012, it was
reported that more than 60% of patients in intensive care suffer from some sort of
AKI, which increases their mortality rate by an astounding 70% [5].
There is a long list of factors leading to the development of AKI.
Complications such as hypertension, cardiovascular disease, medications,
dehydration, surgery, chemotherapy and chronic kidney disease all increase
one’s vulnerability to AKI. Additionally, since kidney function naturally declines
with age, the incidence of AKI in the older population is significantly higher [6].
Both ageing and maladaptive repair after AKI share common mechanisms that
lead to increased risk of progressive chronic kidney disease. These mechanisms
include tubular loss, glomerulosclerosis, senescent tubular epithelia and
interstitial collagen deposition, suggesting that progressive chronic kidney
3

disease is comparable to excessive ageing of the kidney [7]. Due to an
ever aging population, these factors have led to steady increases in hospitalized
patients, particularly among the elderly [8]. Additionally, the financial burden of
AKI to the United States healthcare system has been devastating, with over $1
billion going towards in hospital treatment per year [9].
Given the nature of AKI and the broad definition of when AKI starts, its
frequency is difficult to monitor in a uniform manner. In 2012 alone there were
over 35 different working definitions for AKI [10]. For example, both serum
creatinine and blood urea nitrogen (BUN) are two nitrogenous products that can
be measured to estimate changes in GFR. Serum creatinine and BUN are
normally freely filtered by the kidney. When kidney filtration declines, they
accumulate in circulation. Thus, when the concentrations of these products
increase, a corresponding decrease in renal clearance is observed. Due to a lack
on uniformity in defining AKI, there has been a push in the field to use changes in
both serum creatinine and BUN, as well as other biomarkers, to more uniformly
define to uniformly define AKI [8].
In an effort to create more uniform criteria for the diagnosis of AKI, the
RIFLE (Risk/Injury/Failure/Loss/End-stage renal disease) and AKIN
classifications (Acute Kidney Injury Network) were developed and published. The
RIFLE scale classifies kidney injury by severity, with categories of risk, injury,
and failure. It further classifies kidney injury outcomes as either loss of function or
end stage renal disease [10]. By the RIFLE definition, AKI is diagnosed upon a
doubling in patient serum creatinine from baseline and a 50% reduction in
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glomerular filtration rate (GFR), with urine output dropping below 0.5 ml/kg/hr for
12 hours [10]. Renal function must decline to these levels in under 7 days and
remain below these baselines for at least 12 hours. To further unify classification
standards, AKIN published their guidelines in 2007 as an additional classification
system. The main difference in the two classification is the fact that AKIN
standards do not require estimation of baseline serum creatinine (compared to a
doubling of serum creatinine from baseline under RIFLE conditions). Additionally,
the AKIN classification system only diagnoses AKI after the patient achieves
adequate hydration, which is difficult to track. These are important differences as
the baseline serum creatinine is not always known and dehydration alone will
negatively impact kidney function and can cause AKI. The levels of AKI
classification in the AKIN classification system are 1, 2, or 3 based on the
increase of serum creatinine within 48 hours from hydration; the risk, injury, and
failure levels of RIFLE classification correspond to levels 1, 2 and 3 in the AKIN
system. For example, in stage 1 of the AKIN system, AKI is defined as an
increase of 0.3 mg/dl serum creatinine and a drop in urine output below 0.5
mg/kg/hr for a period of 6 hours[10]. When a patient enters the clinic, their injury
is typically judged based on both RIFLE and AKIN as classifications determined
by the Kidney Disease Improving Global Outcomes (KDIGO) group. The
diagnosis of AKI is based on either a 0.3 mg/dl increase of serum creatinine
within 2 days or a doubling of serum creatinine from estimated baseline occurring
within 7 days [10].
Biomarkers of AKI
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As mentioned previously, defining AKI is difficult because of the different
standards held in clinics around the world. While monitoring serum creatinine is a
mildly concrete scale, it has its flaws. One downside to using serum creatinine is
that it does not become elevated until 24-72 hours after a renal insult with a 50%
loss in nephrons [3]. For example, a 0.3 mg/dl rise in serum creatinine
(approximately a 50% increase) can reflect many different phenotypes,
depending on the patient. A 50% serum creatinine rise for an ICU patient with
sepsis and hypotension would indicate a poor prognosis, aggressive treatment
management and structural kidney damage. On the contrary, a 50% rise in
serum creatinine for a patient experiencing congestive heart failure while on
diuretic therapy would reflect a hemodynamic rise in creatinine, with no structural
damage [9]. On the contrary, a 50% rise in serum creatinine for a patient
experiencing congestive heart failure while on diuretic therapy would reflect a
hemodynamic rise in creatinine, with no structural damage [11]. These are two
significantly different clinical diagnoses with only minor differences in serum
creatinine. Additionally, subclinical AKI is a condition where kidney injury occurs
without a rise in serum creatinine. While this is less common and often a milder
form of AKI, it still may result in long-term alterations in kidney function.
Therefore, defining AKI solely off serum creatinine is limited because it does not
account for AKI etiology, prognosis, molecular pathways or treatment responses
[11]. Defining AKI by measuring BUN is another widely accepted way to monitor
AKI. As with serum creatinine, BUN also has its limitations in determining GFR;
the spike in BUN occurs 24 hours to days after the injury. It is also affected by
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many factors besides AKI, such as race, age, body weight, metabolism, sex and
protein intake [5]. In order to more effectively treat and diagnose AKI, other more
sensitive biomarkers that can be detected immediately following injury are
needed and must also be considered in the diagnosis.
Due to the mortality of persistent AKI, it has become more important than
ever to find biomarkers of AKI in the clinic with higher specificity and sensitivity.
The ideal biomarker would allow early identification of AKI in the clinic, with a
variety of treatment options depending on the timeline of the injury. Due to the
time dependence of BUN and serum creatinine as it relates to GFR, newer
biomarkers are being investigated, including neutrophil gelatinase-associated
lipocalin (NGAL) and kidney injury marker 1 (Kim-1).
Kim-1 is a cell surface receptor in epithelial and lymphoid/myeloid cells
whose expression has been shown to increase significantly during AKI and other
inflammatory responses [12]. Kim-1 has a limiting role in the immune response to
injury since it is known that phagocytosis of apoptotic bodies can limit the
proinflammatory response [13]. Kim-1 mRNA and protein levels are low in the
healthy kidney, but increase significantly in most typed of AKI. During an
ischemic/toxic renal injury, the extracellular domain of Kim-1 is separated from
the membrane and is excreted into the urine [12]. It has been reported that
during AKI, the ectodomain shedding leads to a 100-fold increase in Kim-1 levels
[12]. In models of cisplatin toxicity, Kim-1 has been a better predictor of toxicity
when compared to NGAL and serum creatinine [14]. Both human and animal
studies report a higher specificity from Kim-1 in detecting nephrotoxicity in
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response to the chemotherapeutic cisplatin that serum creatinine [15].
Additionally, histological changes in AKI patients are closely related to rises in
urinary Kim-1. In a meta-analysis consisting of 2979 patient samples, rises in
Kim-1 levels relating to the diagnosis of AKI was scored at 86%, with specificity
to AKI scored at 70% [12]. On the contrary, there are studies showing Kim-1 is
produced by the liver in response to liver injury, limiting its specificity in
diagnosing AKI [16]. The liver-type fatty acid-binding protein, which is another
marker of tubular injury, is positively correlated with Kim-1 expression as early as
2-3 days following injury [16]. Despite these supporting data, larger studies for
validation are still needed for Kim-1. Kim-1 has been approved by the US FDA as
a biomarker for preclinical drug development and may play a significant role in
clinically defining AKI in the future [17].
The discovery of NGAL as a biomarker for AKI was based on animal
studies where early elevations in NGAL were documented in the urine in multiple
models of AKI, including ischemic and nephrotoxic insults (see chapter 3 that
discusses different causes of AKI and the corresponding animal models) in the
early 2000’s[18]. It was first recognized in neutrophils, but it can also function as
a rapid response protein for tissue injury [19]. Despite moderate success in
animal studies, NGAL as a biomarker in the clinic has mixes results in predicting
AKI due to lack of specificity. For example, NGAL is a sensitive marker for kidney
tissue damage and AKI, but it has also been shown to elevate in other acute and
chronic inflammatory conditions[18]. Despite the lack of specificity, an assay
specific for kidney secreted NGAL would greatly increase its use in the clinic.
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Types and causes of AKI
There are three main classifications of AKI, namely prerenal, acute
postrenal and intrinsic renal AKI, such as toxin-induced tubular injury. Intrinsic
AKI represents true kidney disease, while post and pre-renal injuries are
consequences of extra-renal diseases that affect GFR [20]. Prerenal injury
results from decreased renal prefusion or volume depletion. Intrinsic injury results
from direct injury or physical disruption to the kidneys. Postrenal injury occurs
when there is insufficient urine drainage distal to the kidneys [6]. All three
manifestations of AKI etiologies will be discussed here, with the heavier focus
being on ischemic and nephrotoxic injury.
Pre-renal AKI is defined by conditions of normal tubular and glomerular
function. In pre-renal AKI, hypoperfusion (inadequate blood supply to the kidney)
results in a decrease in GFR as an adaptive technique to extra-renal insults [20].
The four main abnormalities leading to pre-renal AKI are: hypovolemia, impaired
cardiac function, systemic vasodilatation and increased vascular resistance.
These abnormalities can arise from a number of causes such as hemorrhages,
congestive heart failure, cirrhosis, anesthesia, anaphylaxis, renal fluid loss,
severe dehydration, liver disease, cardiac surgery, kidney transplants or
myocardial infarction [20]. The body’s normal responses to pre-renal AKI is to
reabsorb sodium in an effort to increase intravascular volume and renal perfusion
[4]. Therefore, the focus of pre-renal AKI treatment is aimed at restoring renal
perfusion via pharmaceuticals. The majority of the time pre-renal AKI treatment
focusses on correcting the cause of injury, with drugs such as angiotensin-
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converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal
anti-inflammatory agents decreasing the glomerular filtration rate by changing the
balance of vasodilatory agents in circulation [8]. Kidney function usually restores
itself within a couple days, once the underlying cause has been taken care of and
normal blood flow has been restored [20].
Post-renal causes of AKI are described as disrupting urinary flow,
increasing intratubular pressure and thereby decreasing GFR [4]. Acute urinary
tract obstructions can impair renal blood flow and trigger an inflammatory
response that can decrease GFR [4]. Normally the obstruction involves both
kidneys or one solitary kidney to induce significant renal failure, but there are
cases where people with preexisting renal deficiencies develop AKI with the
obstruction of one kidney [4]. Some more common types of urinary obstruction
leading to post-renal AKI are prostatic hyperplasia/prostate cancer in males,
gynecologic cancers (i.e. cervical cancer) in women, ureteral stones, papillary
necrosis and neurogenic bladder to name a few [11].
Intrinsic AKI is the most common form of AKI acquired in hospitalized
patients, accounting for up to 70% of cases [21]. Intrinsic forms of AKI are more
difficult to classify because there are a variety of injury types that can occur
based on the structural target. For simplicity, acute glomerular nephritis, acute
interstitial nephritis, and acute tubular necrosis are the 3 major classifications of
intrinsic AKI. These classifications are named based on insult to glomeruli, the
tubules, the interstitium or the intrarenal blood vessels [4]. AKI resulting from
damage to the tubules is referred to as acute tubular necrosis (ATN). Eighty to
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ninety percent of the cases of acute tubular necrosis are a result of ischemic or
nephrotoxic injury[22]. Both ischemic and nephrotoxic injuries involve several
pathophysiological processes, including endothelial damage and vascular
impairment, immune response, and tubular cell death [21]. These
pathophysiological processes orchestrate AKI development in phases of
initiation, extension, maintenance, and recovery [21].
During the initiation phase, the ischemic or nephrotoxic injury triggers
functional damage to tubule epithelial cells. As a result, this decreases renal
blood flow, causing a decrease in available cellular ATP [21]. Following ATP
shortages, the inflammatory response is triggered, alongside morphological
changes in epithelial cells [21]. The extension phase consists of the subsequent
hypoxia and inflammatory response. Inflammatory and profibrotic cells begin
infiltrating and proliferating, leading to tubule cell death and a continued decline
in GFR [21]. In the maintenance phase, the decline in GFR halts as tubule cells
begin dedifferentiation, migration, and proliferation [21]. Finally, renal function
returns in the recovery phase. During this stage, renal epithelial cells re-establish
polarity and return to normal function, while inflammatory and profibrotic cells are
cleared [21]. The extent to which kidney function recovers depends heavily on
which section of the nephron is injured and the extent of the injury.
The first category of ATN is ischemia reperfusion injury (IRI). IRI can
induce both primary and secondary incidents, depending on the segment of the
nephron most directly injured. For the most part, IRI studies focus on the last
segment of the proximal tubule and the medullary thick ascending limb[22]. Both
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of these segments are susceptible to ischemic events due to their location in the
medulla, which is normally hypoxic [22]. The second classification of ATN is from
nephrotoxic causes such as exogenous compounds like chemotherapeutics and
environmental toxicants [4]. These toxins injure specific sections of the nephron
depending on the mechanism and have helped additional kidney biomarkers be
recognized and developed. For example, myoglobin, a toxic protein released into
circulation during rhabdomyolysis, is filtered through the glomerulus and
reabsorbed in the proximal tubule, where it induces death to the epithelia [4].
Historically, ATN goes through an oliguric (urine output ≤ 400 mL/24 hours) and a
nonoliguric (urine output > 400 mL/day) phase for 1-2 weeks each before the
recovery of renal function[4]. AKI from glomerular damage also significantly
affects GFR and occurs often in cases of acute glomerulonephritis [1]. This can
be a result of a number of primary renal diseases, such as idiopathic rapidly
progressive glomerulonephritis, or it can result from systemic diseases such as
lupus erythematosus or Wegener’s granulomatosis[4]. AKI from interstitial
damage often arises after an allergic reaction to a variety of medications and
infections. For example, antibiotics such as sulfonamides can induce crystalluria
and acute interstitial nephritis [4]. Finally, AKI from vascular tissues can occur
when intrarenal vessel become damaged, leading to decreased renal perfusion
and diminished GFR[4].
Chronic Kidney Disease
For many years it was generally accepted that patients who survived AKI
would recover to full kidney functionality. However, recent epidemiological
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studies suggest that survivor of AKI exhibit a consistently higher risk of
developing Chronic Kidney Disease (CKD) and cardiovascular mortality [7].
Maladaptive repair of following AKI is a pressing issue, resulting in progressive
fibrosis and tubular loss [23]. CKD is defined as a steady loss of kidney function
and accumulating kidney damage, measured by albumin in urine. CKD is
typically associated with interstitial fibrosis, glomerulosclerosis, and chronic
inflammation[7].
Normally, CKD is diagnosed if patients progress to the failure stage of the
RIFLE classification for over 3 months [10]. At this point, patients have over 75%
reduction if GFR and have to be put on dialysis due to a lack of treatment options
for CKD. Dialysis can slow the progression of kidney disease temporarily; these
patients will eventually lose kidney function (complete loss of function for more
than 4 weeks) and will develop end stage renal disease (complete loss of
function for more than 3 months) [7]. Once patients reach end stage, the only
survival option is a renal transplant [24].
CKD prevalence has been gradually increasing over the past 25 years,
effecting older populations at alarming rates[25]. Over 60% of people aged 80
years or older have diagnosed CKD, defined by nature as a glomerular filtration
rate <60 ml/min [6]. As of 2017, CKD was estimated to affect 13.4% of people
globally; the CDC has recently reported over 15% of US adults have CKD, with
37 million citizens going undiagnosed. “In 2018, treating Medicare beneficiaries
with CKD cost over $81.8 billion, and treating people with ESRD cost an
additional $36.6 billion” [26]. That ends up being nearly $23,000 per person in
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Medicare spending. Generally, CKD development is associated with old age,
hypertension, diabetes, cardiovascular disease, and obesity, all of which are
highly prevalent in the US population [6].
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MODELS OF AKI
Due to the unmet medical need for more effective therapies for patients
with AKI, it is important to understand the numerous different preclinical AKI
models currently being used. The purpose of this chapter is to examine some of
the different AKI animal models are being used in order to determine which
models are the most appropriate in modeling human AKI. As mentioned
previously, the three main classifications of AKI prerenal, acute postrenal and
intrinsic renal AKI. Currently, the most common way to study AKI and renal
transplantation is with ischemia reperfusion (IR) models. Renal ischemia
reperfusion at its most basic definition is a temporary impairment and eventual
restoration of blood and oxygen flow to the kidney, which results in a cascade of
cell death, injury, inflammation and fibrosis [27]. A large variety of IR models are
used to study prerenal AKI, which occurs in many clinical situations such as
vessel occlusion during surgeries, postoperative hypofusion, bleeding,
dehydration, shock and sepsis [27]. While there are a variety of IR models, the
three most prevalent are bilateral renal clamping, unilateral renal clamping and
unilateral renal clamping with a contralateral nephrectomy [28]. These IR models
can be performed in a variety of ways, with variables such as ischemia time,
temperature control, clamp time and animal choice having a large effect on the
outcomes.
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Bilateral IR induces kidney injury by blocking the blood flow to both renal
arteries, which is more relevant to human studies because injured patients often
have impaired blow flow to both kidneys [27]. Additionally, only bilateral clamping
influences overall renal mass and leads to SCr and BUN level elevations in under
24 hours, which translates to AKI in the clinical setting [28]. One major fallback
with bilateral clamping is the consistency in controlling the extent of renal injury.
For example, one study found that 22-25 minutes of clamping in C57BL/6 mice
will successfully induce mild to moderate injury with a full function recovery in
less than a week. However, 25-30 minutes of ischemia was shown to induce
severe injury, killing a large proportion of the C57BL/6 mice in under 48 hours
[29]. This suggests that ischemia times must be long enough to induce tubular
necrosis and meet AKI criteria, but mice mortality severely limits using bilateral
IR when examining long term outcomes [30]. While long term studies with
bilateral IR injury have been done, most studies indicate normal kidney
morphology within 2 weeks of the injury [31]. As a result, unilateral IR models are
more commonly used to study AKI beyond the initial injury phase.
Unilateral IR injury is induced by blocking the flow to one kidney, while the
contralateral kidney remains functional and intact. Generally speaking, this model
is used more for long term animal studies to study the mechanism of the AKI to
CKD transition. For example, Zager et al. implemented 30 minutes of unilateral
ischemia and made assessments up to 3 weeks later. They found prevalent
necrosis in the proximal tubules at day 1 following injury and the this phenotype
persisted to increased inflammation, fibrosis and histone modifications in the
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week 3 assessment [32]. Similarly, Lech et al. noted significant pathological
changes just days following the injury, with decreased kidney weight and
corresponding fibrosis, tubular atrophy and inflammation up to 10 weeks post
injury [33]. This suggests unilateral IR models have significant potential for long
term studies, with a decreased risk of animal mortality due to the presence of a
fully functional contralateral kidney. Additionally, longer clamping times can be
utilized in this model to induce a more consistent and extensive AKI when
compared to the bilateral model. The major pitfall of unilateral IR injury is the
difficult in monitoring functional renal decline due to the presence of a fully
functional kidney compensating after injury [27]. The third model is unilateral
clamping and removal of the contralateral kidney in order to increase blood
reflow to the injured kidney and avoid the compensation issue mentioned above.
Compared to leaving the contralateral kidney intact, this model has been shown
to have lower chances of variations along with proven ischemia for long term
chronic studies of injury [28]. As seen with the unilateral model, the difficulty in
achieving sufficient AKI without mortality limits this model. Skrypnyk et al.
evaluated both mild and moderate induced IR induced AKI and found when the
contralateral kidney was removed, only 50-60% of mice developed sufficient AKI
after 24 hours [34]. Other research groups indicate this model had a 30%
mortality rate in their mice population with large variations when compared to
leaving the contralateral kidney intact [27]. As discussed above, there are
endless models of IR induced renal injury, with varying success depending on
the purpose of each experiment. The most important factors to consider when
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choosing the appropriate model are the drawbacks associated with each model.
Urinary tract obstruction is common cause of renal injury that needs
immediate attention to avoid interstitial fibrosis and irreversible renal injury. The
unilateral ureteral obstruction (UUO) model is important as it helps monitor the
transition from AKI to CKD, focusing on tubular cell injury, inflammation and
fibrosis [35]. UUO is treated by relieving the obstruction, allowing urine to flow
again. During UUO, the intratubular hydrostatic pressure builds up, destroying
nephrons and initiating secondary ischemia downstream of the obstruction [35].
There are quite a few variations between UUO models, mainly focusing on the
duration of the obstruction. Due to advances in surgical techniques, researchers
are able to manipulate models by altering the timing, duration and extent of injury
[36]. Acute obstruction results in AKI, however obstruction for 1-2 weeks is more
common because histological features of CKD become present, allowing
researchers to study fibrosis more quickly than previous models [35]. In general,
male animals are most often used in UUO models because female sex organs
make the procedure more difficult. There are two common variations of unilateral
ureteral obstruction, complete UUO and partial UUO. In complete UUO, the
ureter is ligated and completely cut, which results in interstitial inflammation,
tubular dilation and fibrosis in under 7 days [37]. Complete UUO is beneficial
because of the repeatability and fast progression of fibrosis, however a complete
obstruction is not usually a cause of human renal injury. On the other hand,
partial UUO is performed by inserting a ureter to the surrounding psoas muscle
[36]. While this more closely mimics clinical obstructive nephropathy and allows
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for variable degrees of obstruction, this technique is severely limited by its
reproducibility. Despite some disadvantages of UUO as a model of injury, it is
increasingly popular for identifying molecular mechanisms of inflammation,
apoptosis and fibrosis in the progression of AKI to CKD [38].
Drug-induced nephrotoxicity is one of the largest obstacles to overcome in
the clinical setting because of the kidneys specialized role in filtering substances
from the blood. This makes the kidneys particularly vulnerable to damage of the
tubules, interstitium, glomerulus and puts the patient at risk of chronic kidney
dysfunction [39]. The kidneys are exposed to many nephrotoxicants, ranging
from chemotherapeutics, pharmaceuticals, antimicrobials, drugs of abuse,
environmental toxicants and natural substances, which induce injury through a
variety of mechanisms [39]. The unfortunate limitation of nearly all
pharmaceuticals is nephrotoxicity, emphasizing the need to develop efficient
models monitoring AKI and its progression to CKD. The focus of this section is to
look into some of the drug induced models of nephrotoxicity, focusing primarily
on cisplatin models as an example.
Cisplatin is a commonly used chemotherapeutic for the treatment of a
variety of cancers, such as lung cancer and many solid organ cancers [40]. Along
with many drugs, the dose-limiting factor of cisplatin is off target nephrotoxicity
when it gets transported to renal epithelial cells [40]. In order to mimic clinical
scenarios of drug-induced nephrotoxicity, one recent area of focus has been on
the dosing regimen in animal models of cisplatin injury. Until recently, the most
common rodent model of cisplatin-induced AKI was a single high dose (20
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mg/kg) of cisplatin. This results in a sharp decline in renal function in 3-4 days
before the rodents must be euthanized [41]. In this model, the single high dose of
cisplatin induces significant cell death, triggering cell cycle arrest, acute ER
stress and apoptosis [41]. While this might mimic clinically developed AKI in
severe situations, the single high dose model doesn’t provide information for long
term renal damage. Instead, some newer models focus on extending out the
treatment window by treating mice with low doses over longer period of time. For
example, the Siskind laboratory uses a repeated low-dose cisplatin (RLDC)
regimen, treating mice with 7-9 mg/kg of cisplatin once weekly for 3-4 weeks [42].
This allows the mice to be aged out up to 6 months from treatment, giving better
insights to progressive renal fibrosis and chronic kidney disease. When
compared to the high dose model, the RLDC model is hypothesized to contribute
to lower, chronic levels of ER stress and upregulated autophagy over time [41].
While this mechanism isn’t completely understood, it is clear that different dosing
regimens initiate different pathways of injury. Taken together, these two models
provide valuable insights into the processes triggered following long term and
acute treatments of cisplatin.
In addition to models varying by the dosing regimen, rodent selection is
another important variable to consider in drug induced models of nephrotoxicity.
For example, sex differences have been noted in both humans and mice, where
females are more sensitive to cisplatin induced AKI [43]. Interestingly, female
mice have been shown to be more protected from IR induced AKI, likely due to
hormonal fluctuations [44]. Another important factor in nephrotoxic models is the
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difference in pharmacokinetics between rodents and humans. It has been shown
that the peak plasma concentration of cisplatin in mice is up to 20 times higher
than in humans. Along with an increased plasma concentration, cisplatin has a
much shorter half-life in mice [45]. Together, this demonstrates a quicker
distribution of cisplatin in mice tissues, suggesting mice are at a higher risk of
cisplatin nephrotoxicity. Finally, models of injury resulting from
chemotherapeutics also have to consider the incorporation of cancer into the
models of injury. Some groups have used xenograft models, subcutaneously
inoculating tumors into mice before treating them with chemotherapeutics.
Pabla et al. first utilized this model investigating ovarian cancer, however this
model is limited because tumors are heavily affected by the microenvironment
they originate in [46]. Many newer models focus on using genetically engineered
mice with human cancer driver mutations in order to integrate aging and the
tumor microenvironment when studying the effect of chemotherapeutics. In
conclusion, there are numerous models of AKI, all of which should be tailored to
mimic specific clinical situations. The focus of the next chapter is to introduce
another factor, sphingolipid metabolism, that has been implicated many of the
models of AKI discussed above.
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SPHINGOLIPID METABOLISM
Sphingolipids are complex, bioactive lipids containing a common
sphingoid base as a backbone (Figure 1) [47]. The metabolism and following
sphingolipid signaling is a complex process. This chapter will highlight
sphingolipid metabolism in the context of kidney function, but a more detailed
overview can we found in Gault et al. [48]. For many years the kidneys have
been shown to play an extensive role in sphingolipid metabolism. For example,
many glycosphingolipids are uniquely expressed in renal tissues [49]. Originally it
was thought that the primary role of sphingolipids was to provide structure to
various cell organelles. However, more recent studies highlight the complex
signaling pathways of many different bioactive sphingolipids on a variety of
cellular targets [50]. Studies focusing on how these bioactive lipids effect renal
physiology are of interest right now because the regulation of sphingolipid
metabolism could be used as a therapeutic target in kidney injury[51].
Sphingolipid metabolism is complex because there are numerous
enzyme-catalyzed reactions leading to different signaling molecules in different
areas of the body and in a given cell. Ceramides are at the center of sphingolipid
metabolism, which can be created from a variety of pathways including de
novo synthesis, sphingomyelin hydrolysis, or recycling different sphingolipids [3].
In de novo synthesis, serine palmitoyl transferase condenses serine and
palmitoyl CoA to form 3-ketosphingosine, which is the rate limiting step in de
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novo ceramide synthesis [3]. 3-ketosphingosine then is reduced to
dihydrosphingosine by 3-ketoreductase. A fatty acid is added to
dihydrosphingosine is then acylated by dihydroceramide synthase, also known
as ceramide synthase (CERs), to form dihydroceramide. There are six ceramide
synthase isoforms that have preferences for different length fatty acids, leading
to dihydroceramides (and the downstream metabolites) of different chain lengths.
Dihydroceramide desaturase then desaturates dihydroceramide at the 4/5
position to form ceramide (Figure 2) [49]. Once synthesized, ceramide can be
used in a variety of catabolic or anabolic reactions.
There are a number of pathways leading to more complex bioactive
sphingolipids from ceramide. Ceramide can be used by sphingomyelin synthases
to form sphingomyelin by attaching a phosphocholine head group to the C1
hydroxyl group of ceramide [52]. Glycosylation of ceramide, also at the C1
hydroxyl group, by adding a glucose or galactose will form the hexosylceramides,
glucosylceramides, and galactosylceramides[3]. Hexosylceramides are used to
synthesize even more complex gylcosphingolipids Sphingomyelins and
glycosphingolipids can also be broken down to regenerate ceramide.
Additionally, phosphorylation of ceramide at the C1 hydroxyl group as catalyzed
by ceramide kinase forms ceramide-1-phosphate[3]. Finally, ceramide can be
cleaved to form sphingosine by the action of ceramidases (acid, alkaline and
neutral ceramidases). The sphingosine can then be phosphorylated by
sphingosine kinases 1 or 2 to form sphingosine-1-phosphate (S1P) [53]. S1P can
either be dephosphorylated by S1P phosphatases or be irreversible cleaved by
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S1P lyase to form ethanolamine-1-phosphate and hexadecenal. As with all of
these pathways mentioned, sphingosine can be recycled back to form ceramide
by ceramide synthase enzymes or the reverse activity of ceramidases [3]. It is
thought that balancing key bioactive sphingolipids can regulate several cellular
processes including inflammation, the regulation of reactive oxygen species
(ROS) production, and cell death (apoptosis, necrosis, etc.) [49]. These are all
processes implicated development of acute kidney injury and chronic kidney
disease.
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S1P RECEPTORS AS POTENTIAL TARGETS

As discussed in the previous chapters, there is a clear role for
sphingolipids and the progression of kidney injury. Due to the complexity of
sphingolipid metabolism, there are numerous potential therapeutic targets for
prevention and treatment of kidney injury. The purpose of this chapter is to focus
on some of the most promising potential therapeutic targets for the prevention
and treatment of renal injury, specifically the sphingosine-1-phosphate receptors
(S1PRs). S1P is a natural lysophospholipid known to regulate cell migration,
stress, cell growth, cytoskeletal rearrangement, apoptosis and calcium
homeostasis [54]. It is present in high nanomolar concentrations in serum, where
it associated with albumin and lipoproteins, and low nanomolar concentrations in
cells. S1P is generated from the hydrolysis of ceramide by ceramidase enzymes,
to yield sphingosine and a fatty acid. The sphingosine can be phosphorylated to
produce sphingosine-1-phosphate (S1P) as catalyzed by either of two
sphingosine kinase enzymes, referred to as sphingosine kinase 1 (SK1) and
sphingosine kinase 2 (SK2) [55]. Once generated, S1P can interact with a
number of intracellular targets [56, 57] or be secreted outside of the cell where it
acts a ligand for any of the five different plasma membrane localized S1P gcoupled protein receptors (GCPRs) identified (S1PR1-5). The sphingosine
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kinase-S1P-S1PR axis is drawing increasing attention as a moderator of
fibrogenesis, specifically cardiac and renal fibrosis [58]. (Figure 3)
S1P has been shown to protect from the kidney from injury through a
variety of pro-survival mechanisms by modulating the immune response. The
activation of S1P receptors is known to induce the relocation of B and T
lymphocytes away from the site of injury, potentially limiting the fibrotic response
[3]. FTY720 (fingolimod), a pan agonist of S1P receptors, was approved by the
FDA for the treatment of multiple sclerosis in 2010 to reduce lymphocyte
egress[59]. It drew significant attention in fibrotic models of injury and has been
shown to attenuate AKI in both nephrotoxic and IR models of injury. Suleimen et
al. treated C57BL/6 mice with FTY720 before inducing IR injury and monitored
them for 3, 5, and 7 days. They found the FTY720 treated group had an earlier
recovery of renal function and hypothesized this was due to a decrease in kidney
infiltrating leukocytes [60]. Perry et al. also showed that FTY720 attenuated AKI,
specifically protecting proximal tubule cells, in their single high dose model of
cisplatin induced AKI[61]. To further understand the effect of S1P agonists in a
lymphocyte-independent mechanism, Bajwa et al. investigated IR injury in mice
lacking both T and B lymphocytes. They found that mice lacking T and B
lymphocytes (Rag-1 knockout mice) were only partially protected from IR injury,
while treatment of FTY720 to the deficient mice resulted in significant additional
protection (as presented in Figure 1 of Bajwa et al) [62]. These results suggest
that S1P receptor activation is renoprotective in a mechanism independent of
reduction of lymphocyte egress, namely via their activation in non-T and B-cells,
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perhaps in the tubule cells [62]. Unfortunately, a number of side effects
associated with FTY720 have limited its use in the further studies. The most
common side effect after FTY720 administration is bradycardia, likely due to its
unspecific action across all five S1P receptor types [63]. Additionally, in phase 3
clinical trials, FTY720 triggered the formation of new blood vessels in the eye and
led to macular degeneration and significant vision loss [63]. While the
mechanism leading to these adverse effects isn’t completely understood, it
further highlights the need for the development of selective S1PR agonists. The
majority of pharmacological modulators currently developed lack specificity
amongst the receptors, as demonstrated in Figure 4.
Additional studies to determine the specific S1PR subtype(s) involved in
kidney injury and the progression to chronic kidney disease were not well
understood. However, following the initial success from FTY720 in renal IR injury
models, researchers focused efforts on identifying which S1PR isoform plays the
major role in AKI. To further identify the specific S1PR isoform involved in kidney
injury, Bajwa et al. performed kidney IP studies utilizing the first successful highly
selective S1PR1 agonist, SEW287, and a S1PR1 antagonist, VPC44116. Bajwa
et al., administered SEW287 or VPC44116 to the T- and B-cell deficient Rag-1
KO mice to specifically examine the impact of S1PR activation or inhibition in the
absence of these lymphocytes [62]. Compared to the vehicle group with elevated
serum creatine levels following IR, SEW287 significantly reduced IR injury as
evidenced by the reduction in serum creatinine. However, when SEW287 and
VPC44116 were treated in combination, the protection conferred by SEW287
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alone was completely lost. The serum creatinine data were supported by
morphologic analysis of kidney sections via H&E staining (as presented in Figure
2 in Bajwa et al.), suggesting S1PR1 activation is required for reducing tubule
injury [62]. Importantly, the authors attenuated S1PR1 expression in vivo and in
vitro and found that deficiency in S1PR1 enhanced injury, regardless of the
presence of S1PR1 agonists[62]. In addition to IR injury models of AKI, S1PR1
has also been implicated as renoprotective in cisplatin-induced AKI. In a 2015
study, Bajwa et al. hypothesized that the protective role of FTY720 in their
cisplatin-induced nephrotoxic model was due to S1PR1 activation [64]. They
developed S1PR1 knock out mice and found that cisplatin induced significantly
more damage in this group when compared to the control group [64]. Taken
together, there is clear evidence that S1PR1 activation is renoprotective and
selective S1PR1 agonists provide potential therapeutic targets in kidney injury.
When compared to S1PR1, the other S1P receptors have received less
attention and there is a clear gap in knowledge. Drexler, Y., et al. identified the
major roles of the five S1P receptors (Figure 5) [65], however connecting these
receptors to their role in renal injury has not been fully established. Some data
have been reported for S1PR2 and S1PR3, but data are lacking for S1PR4 and
S1PR5. A role for S1PR2 in renal IR injury was revealed by Park et al. by treating
mice with a selective S1PR2 antagonist. They found that the S1PR2 antagonist
exacerbated IR injury and this was further supported by data demonstrating that
knocking out S1PR2 in mice led to reduced IR injury [66]. This suggests that S1P
signaling through S1PR2 negatively impacts IR injury and that S1PR2 specific
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antagonists would have therapeutic potential; this is in contrast to S1PR1 which
plays a protective role and therefore development of S1PR1 specific agonists for
therapeutic use would be beneficial. An antagonist of S1PR3, suramin, has been
shown to attenuate renal fibrosis in a UUO model of CKD by interacting with
TGF-B signaling [67]. Suramin has also been shown to protect from cisplatininduced AKI [68]. However, suramin is known to have numerous targets and its
protection may be solely via S1PR3. S1PR3 has been associated to blocking the
activation of killer T-cells by dendritic cells, suggesting the loss of S1PR3
reduces the inflammatory response[69]. The mechanisms of action for examples
are not clearly understood, limiting their application to current drug development.
The S1P/S1PR signaling axis is not only a promising target in renal injury,
as it has also been targeted to treat autoimmune disorders, COVID-19,
inflammation, cancer and cardiovascular disease [70] [71]. Consequently, the
drug discovery process has focused on studying the five specific S1P receptors
in detail in order to develop more specific drug agonists. Until this year, only the
crystal structure of an inactive S1PR1 bound to an agonist had been determined.
However, Yuan et al. recently reported cryo-electron microcopy (EM) structure
for both S1PR1 and S1PR5 with ligands bound, providing the ground work for
identifying ligand specificity to activate these receptors [70]. The authors relied
heavily on Siponimod, an orally available S1P agonist structurally similar to
FYT720, to identify the binding pocket of S1PR1/5 [72]. The authors identified a
conserved ligand binding pocket, composed of a hydrophobic cavity and a polar
module, forming a ligand binding pocket similar to LPA receptors [70].
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Additionally, a sub-pocket of the orthosteric site was identified, interacting with
different side groups of established S1P agonists, such as the trimethyl domain
of SEW2871 [70]. Multiple differences between the two receptors were identified,
most notably in the intracellular loops (ICLs). The ICL2 region showed structural
differences resulting in orientation changes around the α5 helix, which is
hypothesized to play a major role in the G-protein selectivity of the receptors [70].
Taken together, this is a huge step in the right direction when it comes to
identifying differences between S1P receptors, opening the door for future drug
development and discovery. However, there is still a deficiency in knowledge
about many specific receptor properties, which will be discussed in more detail
below.
In order for any of the S1P receptors to be serious potential therapeutic
targets moving forward, a lot of information still needs to be uncovered. As
mentioned above, there are currently only working crystal structures for two of
the receptors bound to a pharmacological agent, S1PR1 and S1PR5 [70]. This
lack of structural information on actively bound S1P receptors is a huge limiting
factor when it comes to identifying receptor specific agonists. For example, while
S1PR1 shares many common characteristics with many identified GCPRs, some
distinguishing features were first identified by Hanson et al. in 2012 when
examining the agonist bound receptor [73]. They found that the N-terminus folds
over the top of the bound receptor and can contribute to the binding affinity, while
also forming a helical cap that limits the access to the binding pocket [73]. This is
significant because it helped explain why the S1P ligands are slow to saturate
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the receptor when excess ligand is present [73]. Additionally, the authors
established that the volume of the hydrophobic portion of the ligand plays a vital
role in downstream signaling by altering interactions with conserved polar
residues [73].
All of this structural information helped provide the framework for the
numerous S1PR1 agents currently being researched, but there is still a long way
to go. Once there are better established crystal structures of the receptors, the
specific sequence homologies of the receptors will need to be investigated
further. This will be important in determining the potential of targeting individual
receptors, ensuring they are different enough to selectively target. As reported by
Yuan et al, both S1PR1 and S1PR5 share a highly conserved binding pocket
when bound to the same agonist, highlighting the need for additional active
conformations to be analyzed [70]. The main pitfall of the major commercially
available drugs, such as FTY720 (fingolimod) in treating MS, is the lack of
specificity, thought to contribute to the numerous adverse off target effects and
failed clinical trials [59]. Assuming there will be significant enough sequence
differences to target the individual receptors, either alone or in combination, there
is no doubt there will be clinical applications in the near future in kidney injury
research.
In addition to a sturdier structural analysis of the receptors, additional
studies are needed to determine the distribution of the receptors in specific cell
types. S1PR3, for example, has been shown to be highly expressed in human
breast cancer cells and immune cells, but its distribution in relation to kidney
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injury has not been identified [74]. In the progression of AKI to CKD, it has been
well established that the S1P axis regulates the immune response by recruiting
macrophages, monocytes, lymphocytes and dendritic cells in the priming stage of
fibrogenesis [58]. Consequently, it is important to know how this alters the
distribution of S1P receptors in the kidney in order to target them in the clinic.
This will open up the potential to develop cell type specific inhibitors or
modulators for S1P receptors. Despite a need to further classify differences
between S1P receptors at the structural and cellular level, the S1P axis clearly
has clinical implications in the treatment of kidney injury moving forward.
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FIGURES

Figure 1. Sphingolipid Base Structure
The backbone of s sphingolipid contains a long chain base (blue) linked to a
fatty acid (orange) via amide bond. A polar head group, R (green), is linked to
the OH on C1 depending on the sphingolipid. \\ denotes the number of
carbons. Figure was made using biorender.com
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Figure 2. Sphingolipid Metabolism
Ceramide (red) is at the center of sphingolipid metabolism. The metabolizing
enzymes are in italics and downstream sphingolipids are in bold. Figure was
made using biorender.com

34

Figure 3. Sphingosine-1-Phosphate Signaling
Ceramide is broken down into sphingosine via ceramidase enzymes.
Sphingosine can be phosphorylated by sphingosine kinase enzymes to from
sphingosine-1-phoshate (S1P). S1P initiates cell migration, stress response,
cytoskeletal rearrangement, calcium homeostasis and apoptosis [57]. Figure
was made using biorender.com
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S1P Receptor Modulators and their Selectivity
Pharmacological Agent

Selectivity

Fingolimod (FYT720)
Siponimod (BAF312)
Ozanimod (RPC1063)
Amiselimod (MT-1303)
Etrasimod (APD334)
Ceralifimod (ONO-4641)
Ponesimod (ACT-128800)
VPC44116
SEW2871
Cenerimod
GSK2018682
VPC23153

S1PR1,3,4,5
S1PR1,5
S1PR1,5
S1PR1,4,5
S1PR1,4,5
S1PR1,5
S1PR1
S1PR1,3
S1PR1
S1PR1
S1PR 1,5
S1PR4

Figure 4. Sphingosine-1-Phosphate Receptor Modulators
The selectivity of some S1P modulators currently being evaluated to treat
kidney disease, chronic inflammatory diseases, diabetes and organ failure.
Adapted from McGowan, E.M., et al. [71]
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Figure 5. Location and Key Functions of the S1P Receptors
S1P Receptors are located on specific cells types, such as endothelial cells,
innate cells and immune cells. Their functions vary from innate cell migration
to apoptosis promotion to endocytosis. Adapted from Drexler, Y., et al [65].
Figure was made using biorender.com
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SUMMARY
Acute Kidney Injury is a complex disease that is difficult to diagnose and
has poor outcomes in the clinic. There are currently no treatment options for
patients with AKI, highlighting the need to identify new potential therapeutic
targets. While a lot of attention has been focused on specific sphingolipids or the
enzymes involved in their metabolism, not enough focus has been on targeting
the receptors being acted on. S1P specifically has been shown to play an
important role in numerous models of AKI by signaling through five different
plasma membrane g-coupled protein receptors. Of the five known S1P receptors
discussed above, S1PR1 has drawn the most attention, as S1PR1 receptor
activation is has been shown to be renoprotective. However, there is a clear gap
in knowledge about the individual receptors, as only S1PR1 and S1PR5 have
established crystal structures and individual receptor distribution is largely
unknown. This has made it increasingly difficult to design drugs with receptor
specificity, limiting the application for now. However, once these receptors are
better characterized, targeting the S1P receptors will have huge implications in
treating kidney injury.
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